Eli Lilly Says EloraTZP Cut Weight Up To 23.3% Vs. 14.8% For Tirzepatide In Phase 2b Diabetes Trial; Plans Phase 3 In Q4

Loading news article.

Eli Lilly Says EloraTZP Cut Weight Up To 23.3% Vs. 14.8% For Tirzepatide In Phase 2b Diabetes Trial; Plans Phase 3 In Q4 | WAPE

Article summary